Pathogen inactivation treatment of triple-dose apheresis platelets with amotosalen and ultraviolet a light

Abstract

Background: A triple storage (TS) set allows for pathogen inactivation (PI) treatment of triple-dose apheresis platelet products with amotosalen + UVA. We evaluated the quality and metabolic parameters of platelet concentrates (PCs) pathogen inactivated and stored for 7 days.

Materials and methods: Twelve triple-dose products collected with two different apheresis platforms were treated with amotosalen+UVA. Products were split into three single-dose units. Testing was made pretreatment, after splitting, at days 5 and 7 of storage.

Results: Single-dose PI PCs had a mean platelet content of 2.89 ± 0.35 x 10¹¹ . From baseline to day 7, pH remained stable (7.1 ± 0.1 vs. 7.0 ± 0.1), pO₂ increased (11.3 ± 2.4 vs. 18.3 ± 3.5 kPa) as did LDH (201 ± 119 vs. 324 ± 203 U/L) and lactate (3.6 ± 1.7 vs. 12.1 ± 1.5 mmol/L) (all p < 0.01); pCO₂ decreased (4.1 ± 0.8 vs. 1.5 ± 0.7 mmHg; p < 0.01) and so did bicarbonate (6.6 ± 1.1 vs. 2.5 ± 1.4 mmol/L), glucose (5.6 ± 1.2 vs. 0.4 ± 0.4 mmol/L) and ATP (3.4 ± 0.9 vs. 2.5 ± 1.4 nmol/10⁸ platelets) (all p < 0.05).

Conclusion: Triple-dose PCs processed with the TS sets fulfilled the quality requirements and displayed metabolic changes of expected extent during 7-day storage.

Keywords: pathogen inactivation; triple-dose apheresis platelet components.

FIGURE 1

Design of the study. Day 1–7: testing for volume and platelet content (units A, B, C). Testing for storage parameters (unit A on day 1, unit B on day 5, unit C on day 7).

FIGURE 2

Schematic view of the INTERCEPT platelet processing set with triple storage containers. The required ranges of platelet content and volume in apheresis products in plasma/PAS (32%–47% plasma content) are 5–12 x 10¹¹ and 420–650 ml, respectively.